XML 57 R40.htm IDEA: XBRL DOCUMENT v3.24.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2023
Share-based Payment Arrangement, Noncash Expense [Abstract]  
Schedule of Stock Options Granted
 
   
Year ended December 31, 2023
 
   
Number
of options
   
Weighted
average
exercise
price
   
Weighted average remaining contractual term
(in years)
   
Aggregate
intrinsic
value
 
                     
$ thousands
 
Outstanding at beginning of year
   
5,305,732
     
2.95
     
3.83
     
19
 
Granted
   
1,466,357
     
2.00
                 
Exercised
   
(22,415
)
   
1.78
                 
Forfeited or expired
   
(1,124,192
)
   
2.93
                 
                                 
Outstanding at end of the year
   
5,625,482
     
2.71
     
3.66
     
300
 
                                 
Options exercisable at end of the year
   
3,182,912
     
2.88
     
2.87
     
72
 
                                 
Vested and expected to vest
   
5,127,051
     
2.74
     
3.54
     
246
 

 

Schedule of RSUs Granted
   
Year ended December 31, 2023
 
   
Number of RSUs
   
Aggregate intrinsic
value
 
         
$ thousands
 
Unvested at beginning of year
   
2,108,339
     
4,027
 
Granted
   
1,328,447
         
Vested
   
(537,323
)
       
Forfeited
   
(277,268
)
       
                 
Unvested at end of the year
   
2,622,195
     
5,664
 
Schedule of Equity-Based Compensation Expense
 
   
Year ended December 31,
 
   
2023
   
2022
   
2021
 
   
$ thousands
   
$ thousands
   
$ thousands
 
Cost of revenues
   
482
     
587
     
289
 
Research and development, net
   
828
     
405
     
236
 
Sales and marketing
   
1,416
     
1,355
     
700
 
General and administrative
   
1,238
     
1,213
     
1,337
 
                         
Total share-based compensation expenses
   
3,964
     
3,560
     
2,562